Stay updated on Subcutaneous Nivolumab + rHuPH20 Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Nivolumab + rHuPH20 Clinical Trial page.

Latest updates to the Subcutaneous Nivolumab + rHuPH20 Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has undergone significant content changes, including the removal of detailed study information regarding nivolumab and its associated criteria, while adding a new section titled 'Neoplasms by Site' and updating the revision number to v2.15.0.SummaryDifference7%
- Check29 days agoChange DetectedThe page has updated its version from v2.14.3 to v2.14.4 and removed a date of 2025-03-25 while adding dates of 2025-01-29 and 2025-02-20.SummaryDifference0.7%
- Check37 days agoChange DetectedThe page has been updated to reflect new dates and a revision change, indicating a more current version of the content. The previous estimated dates and version have been removed.SummaryDifference0.7%
- Check73 days agoChange DetectedThe webpage has been updated with new clinical trial data regarding the pharmacokinetics of nivolumab, including details on maximum serum concentration (Cmax), time to reach Cmax (Tmax), and area under the concentration-time curve (AUC). Additionally, new reporting dates for results have been added.SummaryDifference73%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
Stay in the know with updates to Subcutaneous Nivolumab + rHuPH20 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Nivolumab + rHuPH20 Clinical Trial page.